J&J has been rapidly building its portfolio in both medical technology and drug development to help prepare for the impending loss of exclusivity for Stelara, its top-selling drug for psoriasis.
United already had planned several changes, including an additional day of in-person training for pilots starting in May, and a centralized curriculum for new maintenance technicians.